ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial

Malcolm Ranson, Lisa A. Hammond, David Ferry, Mark Kris, Andrew Tullo, Philip I. Murray, Vince Miller, Steve Averbuch, Judy Ochs, Charles Morris, Andrea Feyereislova, Helen Swaisland, Eric K. Rowinsky

Research output: Contribution to journal › Article › peer-review